Metabolic dysfunction in diabetic cardiomyopathy

Heart Failure Reviews

Volumn 19, Issue 1, 2014, Pages 35-48

  Isfort, Michael ^a,b   Stevens, Sarah C W ^b   Schaffer, Stephen ^c   Jong, Chian Ju ^c   Wold, Loren E ^b,d  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF SOUTH ALABAMA   (United States)

^d OHIO STATE UNIVERSITY   (United States)

Author keywords

Diabetes; Diabetic cardiomyopathy; Heart failure; Mitochondria; Oxidative stress

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARNITINE PALMITOYLTRANSFERASE I; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; GLUCOSE TRANSPORTER 1; GLUCOSE TRANSPORTER 4; GLUTATHIONE; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PROTEIN KINASE C; PYRUVATE DEHYDROGENASE KINASE; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

CALCIUM HOMEOSTASIS; CARDIOVASCULAR DISEASE; CATALYSIS; CELL METABOLISM; DIABETIC CARDIOMYOPATHY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOWN REGULATION; ECHOCARDIOGRAPHY; ENERGY METABOLISM; ENZYME DEGRADATION; FATTY ACID METABOLISM; FATTY ACID OXIDATION; GLUCOSE METABOLISM; GLYCEMIC CONTROL; GLYCOLYSIS; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE HYPERTROPHY; HEART OUTPUT; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN METABOLISM; INSULIN RELEASE; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PREVALENCE; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; REVIEW; SEX DIFFERENCE;

DIABETIC CARDIOMYOPATHIES; ENERGY METABOLISM; HUMANS; METABOLIC DISEASES; OXIDATIVE STRESS; PROGNOSIS; VENTRICULAR FUNCTION;

EID: 84899092514     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-013-9377-8     Document Type: Review

References (127)

1. Roger VL, Go AS, Lloyd-Jones DM et al (2012) Heart disease and stroke statistics - 2012 update: a report from the American Heart Association. Circulation 125:e2-e220
2. Anand SS, Yusuf S (2011) Stemming the global tsunami of cardiovascular disease. Lancet 377:529-532
3. Yach D, Stuckler D, Brownell KD (2006) Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nat Med 12:62-66 (Pubitemid 43050076)
4. Shao CH, Rozanski GJ, Patel KP et al (2007) Dyssynchronous (non-uniform) Ca2? release in myocytes from streptozotocin-induced diabetic rats. J Mol Cell Cardiol 42:234-246 (Pubitemid 44958613)
5. Pereira L, Matthes J, Schuster I et al (2006) Mechanisms of [Ca2+]i transient decrease in cardiomyopathy of db/db type 2 diabetic mice. Diabetes 55:608-615 (Pubitemid 43343216)
6. Schafer SA, Machicao F, Fritsche A et al (2011) New type 2 diabetes risk genes provide new insights in insulin secretion mechanisms. Diabetes Res Clin Pract 93(Suppl 1):S9-S24
7. An D, Rodrigues B (2006) Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 291:H1489-H1506 (Pubitemid 44497651)
8. Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115:3213-3223 (Pubitemid 47012236)
9. Barlovic DP, Soro-Paavonen A, Jandeleit-Dahm KA (2011) RAGE biology, atherosclerosis and diabetes. Clin Sci (Lond) 121:43-55
10. Duncan JG (2011) Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim Biophys Acta 1813:1351-1359
11. Department of Health and Human Services CfDCaP (2011) Atlanta. GA. National Diabetes Fact Sheet, National Estimates and General Information on Diabetes and Prediabetes in the United States
12. Garcia MJ, McNamara PM, Gordon T et al (1974) Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 23:105-111
13. Ren J, Ceylan-Isik AF (2004) Diabetic cardiomyopathy: do women differ from men? Endocrine 25:73-83 (Pubitemid 41271131)
14. Schilling JD, Mann DL (2012) Diabetic cardiomyopathy: bench to bedside. Heart Fail Clin 8:619-631
15. Lacombe VA, Viatchenko-Karpinski S, Terentyev D et al (2007) Mechanisms of impaired calcium handling underlying subclinical diastolic dysfunction in diabetes. Am J Physiol Regul Integr Comp Physiol 293:R1787-R1797 (Pubitemid 350085654)
16. Howarth FC, Qureshi MA, Hassan Z et al (2011) Changing pattern of gene expression is associated with ventricular myocyte dysfunction and altered mechanisms of Ca2+ signalling in young type 2 Zucker diabetic fatty rat heart. Exp Physiol 96:325-337
17. Wold LE, Dutta K, Mason MM et al (2005) Impaired SERCA function contributes to cardiomyocyte dysfunction in insulin resistant rats. J Mol Cell Cardiol 39:297-307 (Pubitemid 40995019)
18. Fang ZY, Prins JB, Marwick TH (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25:543-567 (Pubitemid 39096070)
19. McGavock JM, Lingvay I, Zib I et al (2007) Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 116:1170-1175 (Pubitemid 47360218)
20. Ng AC, Delgado V, Bertini M et al (2010) Myocardial steatosis and biventricular strain and strain rate imaging in patients with type 2 diabetes mellitus. Circulation 122:2538-2544
21. Greer JJ, Ware DP, Lefer DJ (2006) Myocardial infarction and heart failure in the db/db diabetic mouse. Am J Physiol Heart Circ Physiol 290:H146-H153
22. Hoshida S, Yamashita N, Otsu K et al (2000) Cholesterol feeding exacerbates myocardial injury in Zucker diabetic fatty rats. Am J Physiol Heart Circ Physiol 278:H256-H262 (Pubitemid 30101878)
23. Fauconnier J, Andersson DC, Zhang SJ et al (2007) Effects of palmitate on Ca(2+) handling in adult control and ob/ob cardiomyocytes: impact of mitochondrial reactive oxygen species. Diabetes 56:1136-1142 (Pubitemid 46525069)
24. Graham ML, Janecek JL, Kittredge JA et al (2011) The streptozotocin- induced diabetic nude mouse model: differences between animals from different sources. Comp Med 61:356-360
25. Wold LE, Ren J (2004) Streptozotocin directly impairs cardiac contractile function in isolated ventricular myocytes via a p38 MAP kinase-dependent oxidative stress mechanism. Biochem Biophys Res Comm 318:1066-1071 (Pubitemid 38625884)
26. Corsetti JP, Sparks JD, Peterson RG et al (2000) Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats. Atherosclerosis 148:231-241 (Pubitemid 30064454)
27. Tokuyama Y, Sturis J, DePaoli AM et al (1995) Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 44:1447-1457
28. Iida M, Murakami T, Ishida K et al (1996) Phenotype-linked amino acid alteration in leptin receptor cDNA from Zucker fatty (fa/fa) rat. Biochem Biophys Res Commun 222:19-26 (Pubitemid 26160051)
29. Martin SS, Qasim A, Reilly MP (2008) Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease. J Am Coll Cardiol 52:1201-1210
30. Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6:772-783 (Pubitemid 44453463)
31. Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820
32. Randle PJ, Garland PB, Hales CN et al (1966) Interactions of metabolism and the physiological role of insulin. Recent Prog Horm Res 22:1-48
33. Neely JR, Morgan HE (1974) Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol 36:413-459
34. Sambandam N, Lopaschuk GD (2003) AMP-activated protein kinase (AMPK) control of fatty acid and glucose metabolism in the ischemic heart. Prog Lipid Res 42:238-256 (Pubitemid 36411693)
35. Chappell JB, Robinson BH (1968) Penetration of the mitochondrial membrane by tricarboxylic acid anions. Biochem Soc Symp 27:123-133
36. Finck BN, Lehman JJ, Leone TC et al (2002) The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest 109:121-130 (Pubitemid 34052548)
37. Schaffer SW, Seyed-Mozaffari M, Cutcliff CR et al (1986) Postreceptor myocardial metabolic defect in a rat model of non-insulin-dependent diabetes mellitus. Diabetes 35:593-597 (Pubitemid 16085334)
38. Serpillon S, Floyd BC, Gupte RS et al (2009) Superoxide production by NAD(P)H oxidase and mitochondria is increased in genetically obese and hyperglycemic rat heart and aorta before the development of cardiac dysfunction. The role of glucose-6-phosphate dehydrogenase-derived NADPH. Am J Physiol Heart Circ Physiol 297:H153-H162
39. Li SY, Sigmon VK, Babcock SA et al (2007) Advanced glycation endproduct induces ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes. Life Sci 80:1051-1056 (Pubitemid 46204720)
40. Yan SF, Ramasamy R, Bucciarelli LG et al (2004) RAGE and its ligands: a lasting memory in diabetic complications? Diab Vasc Dis Res 1:10-20
41. Fulop N, Mason MM, Dutta K et al (2007) Impact of Type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart. Am J Physiol Cell Physiol 292:C1370-C1378 (Pubitemid 46631744)
42. Hu Y, Belke D, Suarez J et al (2005) Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. Circ Res 96:1006-1013 (Pubitemid 40712801)
43. Clark RJ, McDonough PM, Swanson E et al (2003) Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem 278:44230-44237 (Pubitemid 37377167)
44. Cotter MA, Cameron NE, Robertson S (1992) Polyol pathway-mediated changes in cardiac muscle contractile properties: studies in streptozotocin-diabetic and galactose-fed rats. Exp Physiol 77:829-838
45. Trueblood N, Ramasamy R (1998) Aldose reductase inhibition improves altered glucose metabolism of isolated diabetic rat hearts. Am J Physiol 275:H75-H83
46. Ojaimi C, Kinugawa S, Recchia FA et al (2010) Oxidant-NO dependent gene regulation in dogs with type I diabetes: impact on cardiac function and metabolism. Cardiovasc Diabetol 9:43
47. Du XL, Edelstein D, Rossetti L et al (2000) Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci USA 97:12222-12226
48. Nishikawa T, Edelstein D, Du XL et al (2000) Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790 (Pubitemid 30212409)
49. Pacher P, Szabo C (2007) Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev 25:235-260 (Pubitemid 47547464)
50. Du X, Matsumura T, Edelstein D et al (2003) Inhibition of GAPDH activity by poly(ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 112:1049-1057 (Pubitemid 38056320)
51. Schaffer SW, Jong CJ, Mozaffari M (2012) Role of oxidative stress in diabetes-mediated vascular dysfunction: unifying hypothesis of diabetes revisited. Vascul Pharmacol 57:139-149
52. Wieland O, Siess E, Schulze-Wethmar FH et al (1971) Active and inactive forms of pyruvate dehydrogenase in rat heart and kidney: effect of diabetes, fasting, and refeeding on pyruvate dehydrogenase interconversion. Arch Biochem Biophys 143:593-601
53. Hansford RG, Cohen L (1978) Relative importance of pyruvate dehydrogenase interconversion and feed-back inhibition in the effect of fatty acids on pyruvate oxidation by rat heart mitochondria. Arch Biochem Biophys 191:65-81 (Pubitemid 9050309)
54. McCormack JG, Halestrap AP, Denton RM (1990) Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev 70:391-425 (Pubitemid 20140186)
55. Hopkins TA, Sugden MC, Holness MJ et al (2003) Control of cardiac pyruvate dehydrogenase activity in peroxisome proliferator-activated receptor-alpha transgenic mice. Am J Physiol Heart Circ Physiol 285:H270-H276 (Pubitemid 36736438)
56. Campbell FM, Kozak R, Wagner A et al (2002) A role for peroxisome proliferator-activated receptor alpha (PPARalpha) in the control of cardiac malonyl-CoA levels: reduced fatty acid oxidation rates and increased glucose oxidation rates in the hearts of mice lacking PPARalpha are associated with higher concentrations of malonyl-CoA and reduced expression of malonyl-CoA decarboxylase. J Biol Chem 277:4098-4103 (Pubitemid 34968667)
57. Chatham JC, Forder JR (1997) Relationship between cardiac function and substrate oxidation in hearts of diabetic rats. Am J Physiol 273:H52-H58
58. Connelly KA, Kelly DJ, Zhang Y et al (2009) Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail 2:129-137
59. Ricci C, Pastukh V, Leonard J et al (2008) Mitochondrial DNA damage triggers mitochondrial-superoxide generation and apoptosis. Am J Physiol Cell Physiol 294:C413-C422 (Pubitemid 351264418)
60. Luiken JJ, Arumugam Y, Dyck DJ et al (2001) Increased rates of fatty acid uptake and plasmalemmal fatty acid transporters in obese Zucker rats. J Biol Chem 276:40567-40573
61. Coort SL, Willems J, Coumans WA et al (2002) Sulfo-N-succinimidyl esters of long chain fatty acids specifically inhibit fatty acid translocase (FAT/CD36)-mediated cellular fatty acid uptake. Mol Cell Biochem 239:213-219 (Pubitemid 35385812)
62. Lopaschuk GD, Ussher JR, Folmes CD et al (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90:207-258
63. Chabowski A, Coort SL, Calles-Escandon J et al (2004) Insulin stimulates fatty acid transport by regulating expression of FAT/CD36 but not FABPpm. Am J Physiol Endocrinol Metab 287:E781-E789 (Pubitemid 39237909)
64. Luiken JJ, Coort SL, Koonen DP et al (2004) Regulation of cardiac long-chain fatty acid and glucose uptake by translocation of substrate transporters. Pflugers Arch 448:1-15 (Pubitemid 38657200)
65. Carley AN, Severson DL (2005) Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta 1734:112-126 (Pubitemid 40724778)
66. Holland WL, Brozinick JT, Wang LP et al (2007) Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 5:167-179
67. Rodrigues B, Xiang H, McNeill JH (1988) Effect of L-carnitine treatment on lipid metabolism and cardiac performance in chronically diabetic rats. Diabetes 37:1358-1364 (Pubitemid 19035986)
68. Sakamoto J, Barr RL, Kavanagh KM et al (2000) Contribution of malonyl-CoA decarboxylase to the high fatty acid oxidation rates seen in the diabetic heart. Am J Physiol Heart Circ Physiol 278:H1196-H1204 (Pubitemid 30235496)
69. Kudo N, Barr AJ, Barr RL et al (1995) High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 50 -AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270:17513-17520
70. Gamble J, Lopaschuk GD (1997) Insulin inhibition of 5′ adenosine monophosphate-activated protein kinase in the heart results in activation of acetyl coenzyme A carboxylase and inhibition of fatty acid oxidation. Metabolism 46:1270-1274 (Pubitemid 27473509)
71. Young ME, Goodwin GW, Ying J et al (2001) Regulation of cardiac and skeletal muscle malonyl-CoA decarboxylase by fatty acids. Am J Physiol Endocrinol Metab 280:E471-E479
72. Finck BN, Han X, Courtois M et al (2003) A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc Natl Acad Sci USA 100:1226-1231 (Pubitemid 36183984)
73. Chen W, Xia Y, Zhao X et al (2012) The critical role of astragalus polysaccharides for the improvement of PPRAalpha-mediated lipotoxicity in diabetic cardiomyopathy. PLoS ONE 7:e45541
74. Yu BC, Chang CK, Ou HY et al (2008) Decrease of peroxisome proliferator-activated receptor delta expression in cardiomyopathy of streptozotocin-induced diabetic rats. Cardiovasc Res 80:78-87
75. Cheng L, Ding G, Qin Q et al (2004) Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat Med 10:1245-1250 (Pubitemid 39540443)
76. Burkart EM, Sambandam N, Han X et al (2007) Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J Clin Invest 117:3930-3939 (Pubitemid 350224102)
77. Bowman RH (1966) Effects of diabetes, fatty acids, and ketone bodies on tricarboxylic acid cycle metabolism in the perfused rat heart. J Biol Chem 241:3041-3048
78. Taegtmeyer H, Passmore JM (1985) Defective energy metabolism of the heart in diabetes. Lancet 1:139-141 (Pubitemid 15160588)
79. Kuo TH, Moore KH, Giacomelli F et al (1983) Defective oxidative metabolism of heart mitochondria from genetically diabetic mice. Diabetes 32:781-787 (Pubitemid 13038892)
80. Pierce GN, Dhalla NS (1985) Heart mitochondrial function in chronic experimental diabetes in rats. Can J Cardiol 1:48-54 (Pubitemid 15239699)
81. Tomita M, Mukae S, Geshi E et al (1996) Mitochondrial respiratory impairment in streptozotocin-induced diabetic rat heart. Jpn Circ J 60:673-682
82. Boudina S, Sena S, O'Neill BT et al (2005) Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetics in obesity. Circulation 112:2686-2695 (Pubitemid 41532606)
83. Suarez J, Hu Y, Makino A et al (2008) Alterations in mitochondrial function and cytosolic calcium induced by hyperglycemia are restored by mitochondrial transcription factor A in cardiomyocytes. Am J Physiol Cell Physiol 295:C1561-C1568
84. Zungu M, Young ME, Stanley WC et al (2009) Chronic treatment with the peroxisome proliferator-activated receptor alpha agonist Wy-14,643 attenuates myocardial respiratory capacity and contractile function. Mol Cell Biochem 330:55-62
85. Boudina S, Sena S, Theobald H et al (2007) Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 56:2457-2466 (Pubitemid 47523253)
86. von Bibra H, Hansen A, Dounis V et al (2004) Augmented metabolic control improves myocardial diastolic function and perfusion in patients with non-insulin dependent diabetes. Heart 90:1483-1484 (Pubitemid 39626336)
87. von Bibra H, Siegmund T, Hansen A et al (2007) Augmentation of myocardial function by improved glycemic control in patients with type 2 diabetes mellitus. Dtsch Med Wochenschr 132:729-734 (Pubitemid 46739687)
88. McGuire DK, Inzucchi SE (2008) New drugs for the treatment of diabetes mellitus: part I: thiazolidinediones and their evolving cardiovascular implications. Circulation 117:440-449
89. Sharma AM, Staels B (2007) Review: peroxisome proliferator-activated receptor gamma and adipose tissue-understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 92:386-395
90. Masoudi FA, Inzucchi SE (2007) Diabetes mellitus and heart failure: epidemiology, mechanisms, and pharmacotherapy. Am J Cardiol 99:113B-132B
91. Masoudi FA, Inzucchi SE, Wang Y et al (2005) Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111:583-590 (Pubitemid 40216485)
92. Nikolaidis LA, Elahi D, Hentosz T et al (2004) Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110:955-961 (Pubitemid 39128621)
93. Sokos GG, Nikolaidis LA, Mankad S et al (2006) Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12:694-699 (Pubitemid 44881367)
94. Chiasson JL, Josse RG, Gomis R et al (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077 (Pubitemid 34680970)
95. Hanefeld M, Josse RG, Chiasson JL (2005) Alpha-glucosidase inhibitors for patients with type 2 diabetes: response to van de Laar et al. Diabet Care 28:1840 (author reply 1)
96. Konduracka E, Gackowski A, Rostoff P et al (2007) Diabetes-specific cardiomyopathy in type 1 diabetes mellitus: no evidence for its occurrence in the era of intensive insulin therapy. Eur Heart J 28:2465-2471 (Pubitemid 47614285)
97. Haas SJ, Vos T, Gilbert RE et al (2003) Are beta-blockers as efficacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials. Am Heart J 146:848-853 (Pubitemid 37378574)
98. Fonseca V, Bakris GL, Bell DS et al (2007) Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabet Med 24: 759-763 (Pubitemid 47012128)
99. Ramasubbu K, Estep J, White DL et al (2008) Experimental and clinical basis for the use of statins in patients with ischemic and nonischemic cardiomyopathy. J Am Coll Cardiol 51:415-426
100. Stolen TO, Hoydal MA, Kemi OJ et al (2009) Interval training normalizes cardiomyocyte function, diastolic Ca2? control, and SR Ca2+ release synchronicity in a mouse model of diabetic cardiomyopathy. Circ Res 105:527-536
101. Howarth FC, Almugaddum FA, Qureshi MA et al (2010) The effects of heavy long-term exercise on ventricular myocyte shortening and intracellular Ca2+ in streptozotocin-induced diabetic rat. J Diabet Complicat 24:278-285
102. Rubenstrunk A, Hanf R, Hum DW et al (2007) Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 1771:1065-1081 (Pubitemid 47208546)
103. Goa KL, Barradell LB, Plosker GL (1996) Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Drugs 52:725-753 (Pubitemid 26382190)
104. Gross B, Staels B (2007) PPAR agonists: multimodal drugs for the treatment of type-2 diabetes. Best Pract Res Clin Endocrinol Metab 21:687-710 (Pubitemid 350177568)
105. Davidoff AJ, Mason MM, Davidson MB et al (2004) Sucrose-induced cardiomyocyte dysfunction is both preventable and reversible with clinically relevant treatments. Am J Physiol Endocrinol Metab 286:E718-E724 (Pubitemid 38506942)
106. Dong F, Fang CX, Yang X et al (2006) Cardiac overexpression of catalase rescues cardiac contractile dysfunction induced by insulin resistance: role of oxidative stress, protein carbonyl formation and insulin sensitivity. Diabetologia 49:1421-1433
107. Wold LE, Ceylan-Isik AF, Fang CX et al (2006) Metallothionein alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of Ca2+ cycling proteins, NADPH oxidase, poly(ADP-Ribose) polymerase and myosin heavy chain isozyme. Free Radic Biol Med 40:1419-1429
108. Yaras N, Bilginoglu A, Vassort G et al (2007) Restoration of diabetes-induced abnormal local Ca2+ release in cardiomyocytes by angiotensin II receptor blockade. Am J Physiol Heart Circ Physiol 292:H912-H920
109. Shekelle PG, Rich MW, Morton SC et al (2003) Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 41:1529-1538 (Pubitemid 36543372)
110. Sowers JR, Epstein M, Frohlich ED (2001) Diabetes, hypertension, and cardiovascular disease: an update. Hypertension 37:1053-1059 (Pubitemid 32304003)
111. Murarka S, Movahed MR (2010) Diabetic cardiomyopathy. J Card Fail 16:971-979
112. Zaman AK, Fujii S, Goto D et al (2004) Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J Mol Cell Cardiol 37:525-535 (Pubitemid 38953380)
113. Orea-Tejeda A, Colin-Ramirez E, Castillo-Martinez L et al (2007) Aldosterone receptor antagonists induce favorable cardiac remodeling in diastolic heart failure patients. Rev Invest Clin 59:103-107 (Pubitemid 47039542)
114. Shimada T (1993) Correlation between metabolic and histopathological changes in the myocardium of the KK mouse. Effect of diltiazem on the diabetic heart. Jpn Heart J 34:617-626
115. Afzal N, Ganguly PK, Dhalla KS et al (1988) Beneficial effects of verapamil in diabetic cardiomyopathy. Diabetes 37:936-942 (Pubitemid 19043725)
116. Afzal N, Pierce GN, Elimban V et al (1989) Influence of verapamil on some subcellular defects in diabetic cardiomyopathy. Am J Physiol 256:E453-E458
117. Shah TS, Satia MC, Gandhi TP et al (1995) Effects of chronic nifedipine treatment on streptozotocin-induced diabetic rats. J Cardiovasc Pharmacol 26:6-12
118. Higa S, Shimabukuro M, Shinzato T et al (1995) Long-term nifedipine treatment reduces calcium overload in isolated reperfused hearts of diabetic rats. Gen Pharmacol 26:1679-1686 (Pubitemid 26032378)
119. Aneja A, Tang WH, Bansilal S et al (2008) Diabetic cardiomyopathy: insights into pathogenesis, diagnostic challenges, and therapeutic options. Am J Med 121:748-757
120. Suarez J, Scott B, Dillmann WH (2008) Conditional increase in SERCA2a protein is able to reverse contractile dysfunction and abnormal calcium flux in established diabetic cardiomyopathy. Am J Physiol Regul Integr Comp Physiol 295:R1439-R1445
121. Wang M, Zhang WB, Zhu JH et al (2010) Breviscapine ameliorates cardiac dysfunction and regulates the myocardial Ca(2+)-cycling proteins in streptozotocin-induced diabetic rats. Acta Diabetol 47:209-218
122. Giles TD, Ouyang J, Kerut EK et al (1998) Changes in protein kinase C in early cardiomyopathy and in gracilis muscle in the BB/Wor diabetic rat. Am J Physiol 274:H295-H307
123. Liu X, Wang J, Takeda N et al (1999) Changes in cardiac protein kinase C activities and isozymes in streptozotocin-induced diabetes. Am J Physiol 277:E798-E804
124. Malhotra A, Kang BP, Cheung S et al (2001) Angiotensin II promotes glucose-induced activation of cardiac protein kinase C isozymes and phosphorylation of troponin I. Diabetes 50:1918-1926 (Pubitemid 33641614)
125. Shizukuda Y, Buttrick PM (2001) Protein kinase C(epsilon) modulates apoptosis induced by beta -adrenergic stimulation in adult rat ventricular myocytes via extracellular signal-regulated kinase (ERK) activity. J Mol Cell Cardiol 33:1791-1803 (Pubitemid 32977133)
126. Pastukh V, Wu S, Ricci C et al (2005) Reversal of hyperglycemic preconditioning by angiotensin II: role of calcium transport. Am J Physiol Heart Circ Physiol 288:H1965-H1975 (Pubitemid 40418027)
127. Wakasaki H, Koya D, Schoen FJ et al (1997) Targeted overexpression of protein kinase C beta2 isoform in myocardium causes cardiomyopathy. Proc Natl Acad Sci USA 94:9320-9325 (Pubitemid 27357827)